Form 4: Immunic Inc. Director Neermann Reports Stock Option Repricing

Director Joerg Neermann reports adjustments to stock options following stockholder approval to reduce the exercise price of eligible options to $1.72 per share.

Summary

• On March 6, 2024, Joerg Neermann, a director of Immunic, Inc., filed a Form 4 with the SEC.
• The filing reports changes in beneficial ownership of derivative securities, specifically stock options.
• On March 4, 2024, Immunic, Inc. stockholders approved a proposal to reduce the exercise price of eligible employee stock options to the greater of $1.72 and 110% of the closing price on a future repricing date.
• The Board of Directors set the repricing date as March 4, 2024, and determined the exercise price of all eligible options would be repriced to $1.72 per share.
• The Form 4 reflects the cancellation of existing eligible options and the reissuance of those options at the new exercise price of $1.72 per share.
• Neermann was granted 64,959 stock options at an exercise price of $1.72.
• Following the repricing, each eligible option retains its original vesting schedule and expiration date.

Sentiment

Score: 6

Explanation: The document itself is neutral, reporting a procedural change. The repricing could be seen as a positive for employee morale and retention, but also reflects a potentially challenging period for the company's stock price.

Positives

• The repricing of stock options could incentivize employees and align their interests with those of the shareholders.
• The repricing of stock options could improve employee morale.

Industry Context

Stock option repricing is a tool companies use to re-incentivize employees when the stock price has fallen significantly below the original option exercise price. This practice is common in the biotech industry, where stock prices can be volatile due to the inherent risks associated with drug development.

Comparison to Industry Standards

• Stock option repricing is a common practice in the biotech industry, especially for companies with volatile stock prices.
• Many biotech companies, such as Gilead Sciences, Amgen, and Biogen, have used stock options as a key component of their compensation packages to attract and retain talent.
• The specific terms of option grants, including vesting schedules and exercise prices, vary widely across the industry.

Stakeholder Impact

• Shareholders may view the repricing as a positive step to retain and motivate employees.
• Employees holding stock options will benefit from the lower exercise price.
• The repricing has no immediate impact on customers, suppliers, or creditors.

Key Dates